BioComplit to Pursue Technology Special Listing Next Year... "KB Securities as Lead Manager"

[Asia Economy Reporter Hyunseok Yoo] Biocomplet, a company specializing in recombinant proteins and antibody drug development, announced on the 2nd that it has signed an IPO (Initial Public Offering) lead underwriting agreement with KB Securities, aiming for a technology-special listing next year.

KB Securities, appointed as the lead underwriter this time, has recently successfully listed companies such as Syntekata Bio and Bridge Biotherapeutics using the technology-special listing system.

Established in 2005, the technology-special listing system allows venture companies to be listed based on their technological capabilities instead of sales or profitability.

Biocomplet is focusing on strengthening its research and new drug development capabilities based on the core technology and patents of DKK2 recombinant protein, which has functions for angiogenesis and nerve cell regeneration. In particular, DKK2 recombinant protein is expected to be a fundamental solution for cardiovascular diseases, diabetic retinopathy, diabetic neuropathy, and diabetic erectile dysfunction, which currently have no fundamental treatments.

A company representative added, “DKK2 recombinant protein has very high potential as a therapeutic drug and can be widely utilized in the fields of cosmeceuticals and regenerative medicine, making its marketability very high.”

The representative explained, “Not only has the new drug development capability been proven based on abundant clinical experience, but the company is also accelerating overall business, including securing a solid sales structure. Efforts to ensure management transparency across all areas, including internal control and accounting, are also being diligently maintained.”

Seungmok Lee, co-CEO of Biocomplet, stated, “Along with preparations for listing with the lead underwriter KB Securities, we plan to focus on corporate growth and build various cooperative relationships.”

This content was produced with the assistance of AI translation services.